Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Regeneron...

    Regeneron third-quarter profit easily tops Street view on Eylea, Dupixent sales

    Written by Ruby Khatun Khatun Published On 2017-11-11T09:30:19+05:30  |  Updated On 18 Aug 2021 3:48 PM IST

    Regeneron Pharmaceuticals Inc on Wednesday reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand for flagship eye treatment Eylea and its new eczema drug Dupixent, boosting its shares almost 7 percent.


    Eylea's U.S. sales increased 12 percent to $953 million in the quarter, topping analysts' expectations of about $935 million. Sales outside the United States, which are booked by Bayer AG, rose 20 percent.


    The drug gets about 70 percent of its sales for wet age-related macular degeneration, the leading cause of blindness in the elderly, with about 25 percent from diabetic macular edema (DME).



    Regeneron said it sees an opportunity for significant growth in DME for which the majority of patients are either untreated or receiving inferior laser therapy. The company also expects to seek approval in the second half of 2018 for Eylea for another vision-threatening condition related to diabetes, diabetic retinopathy, if Phase III data proves positive.

    Excluding items, Regeneron earned $3.99 per share for the quarter, exceeding analysts' average forecast by 14 cents, according to Thomson Reuters I/B/E/S.


    "The numbers on the quarter were very reassuring for investors," said Leerink Partners analyst Geoffrey Porges. "After what had been a rocky earnings season for the biopharma sector, this was something of a relief."


    Several companies, including Celgene Corp, Gilead Sciences Inc, Biogen Inc and Merck & Co saw steep share price declines after reporting third-quarter results or growth issues for key drugs that disappointed investors.


    Sales of $89 million for Dupixent, previously reported by partner Sanofi, beat analysts' average estimate by about $16 million.


    About 500 new prescriptions a week are being written for the drug for moderate-to-severe atopic dermatitis, a type of eczema, with more than 90 percent of patients refilling their prescriptions, the company said.


    "The Dupixent number suggested continued growth in its initial indication and there's at least one new major indication just around the corner," Porges said.


    Regeneron is about to launch a television ad campaign for Dupixent in hopes of capturing more moderate eczema patients and is awaiting an approval decision for the treatment of severe asthma.


    "We recognize this will be a very competitive area," admitted Chief Executive Len Schleifer.


    However, Regeneron believes Dupixent will be differentiated from rivals because it improves lung function as well as reducing asthma flare-ups.


    The drug is also being tested for nasal polyps and a chronic, allergic inflammatory disease of the esophagus.


    Regeneron's potent but expensive cholesterol fighter Praluent continued to struggle with just $49 million in sales. It has lost market share to Amgen's rival Repatha, while both are still battling barriers to patient access from insurers and pharmacy benefit managers.


    Praluent's future will also hinge on the outcome of an upcoming patent infringement trial brought by Amgen.


    Total revenue, which includes collaboration revenue from partners Sanofi and Bayer, rose 23 percent to $1.50 billion, beating estimates of $1.46 billion.


    Regeneron shares were up $11.15, or 2.8 percent, at $415.54 in late morning trade after earlier climbing as high as $432.50.




    (Reporting by Bill Berkrot in New York and Akankshita Mukhopadhyay in Bengaluru; editing by Sriraj Kalluvila and G Crosse)



    AmgenBiogenCelgene Corpdiabetic macular edemaDupixentEyleaGilead SciencesLen SchleiferMerckpharma newsPraluentprofitRegeneronRepatha®salesSanofithird quarter
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok